+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Haemophilia Therapeutics Market

  • ID: 3161744
  • Report
  • April 2015
  • Region: Global
  • 105 Pages
  • Frost & Sullivan
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
Increased use of recombinant and prophylaxis therapies drives growth

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • Baxter
  • Bayer
  • Behring
  • Biogen Idec
  • Cangene
  • MORE
This research service focuses on the global haemophilia therapeutics market, with a particular focus on recently FDA-approved drugs and late-stage compounds for the treatment of haemophilia A, haemophilia B, inhibitors, and von Willebrand Disease. Pipeline analysis outlines the major FDA-approved haemophilia products, which include those submitted for regulatory review and those in Phase I, II, and III of clinical development. The study also provides an overview of the major clinical trials of recently approved or late-stage pipeline candidates. Novel technologies to extend product half-life and potential future therapies for haemophilia patients have also been discussed.

Newer recombinant therapies are likely to gradually capture the share of the current leading participants, posing more of a long-term threat than a short-term one.

Compelling convenience benefits are required for patients to switch therapies. None of the new rFVIII therapies has shown to extend half-life by more than %.

The new market entrants such as Biogen Idec do not have well-established marketing/sales teams or good relationships with haematologists unlike the global big pharma companies.

Moreover, global participants such as Bayer, Baxter, and Novo Nordisk have their own franchise of modified recombinant therapies in the pipeline to defend their market position.

While the pipeline of recombinant replacement factors are maturing, other newer approaches are in the early phase of clinical development.

Early proof-of-concept studies have shown that gene therapy can be a cost-effective alternative to treat haemophilia B patients.

Companies such as Chatham Therapeutics and Amsterdam Molecular Therapeutics/uniQure are currently investigating new compounds in Phase I trials.

Other novel therapeutics in early-stage pipeline include concizumab, a monoclonal antibody from Novo Nordisk, and ALN-AT3, an RNA interference therapeutic from Alnylam Pharmaceuticals.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • Baxter
  • Bayer
  • Behring
  • Biogen Idec
  • Cangene
  • MORE
1. Executive Summary
  • Executive Summary - Key Findings
  • Haemophilia Drugs Market - Game-changing Strategies
  • Key Merger, Acquisition, and Partnership Assessment
  • Methodology and Scope
2. Introduction
  • Classification of Haemophilia
  • Treatment Guidelines for Haemophilia Therapy - Prophylactic or On-demand
  • Market Overview - Segmentation
3. Haemophilia Therapeutics Market - Epidemiology and Patient Forecasts
  • Haemophilia - Prevalence and Incidence
  • Haemophilia - Global Prevalence and Treatment Rates
4. Haemophilia Therapeutics Market - Trends and Revenue Forecasts
  • Forecast Assumptions and Definitions
  • Haemophilia Therapeutics Market - Revenue Forecast
  • Revenue Forecast Discussion
  • Increasing Use of Recombinant and Prophylactic Treatment
  • Variation in Adoption of Prophylactic Therapy by Region
  • Annual Switching Rates in Haemophilia
  • Global Haemophilia A and vWD Therapeutics Market Revenue Forecast
  • Revenue Forecast Discussion
  • Haemophilia B Therapeutics Market - Revenue Forecast
  • Revenue Forecast Discussion
  • Inhibitors (Bypassing Agents) Market - Revenue Forecast
  • Revenue Forecast Discussion)
5. Haemophilia Therapeutics Market - Marketed Product Analysis
  • Product Analysis - F VIII (Haemophilia A) and FVIII/vWF (vWD)
  • Product Analysis - Factor IX (Haemophilia B)
  • Product Analysis Factor VIIa (Inhibitors)
6. Haemophilia Therapeutics Market - Pipeline Analysis
  • Haemophilia Drugs - Competitive Landscape of Products in Development
  • Haematological Drugs - Pipeline Analysis
  • Pipeline Analysis F VIII (Haemophilia A) and FVIII/VWF (VWD)
  • Pipeline Analysis - F IX (Haemophilia B)
  • Pipeline Analysis - F VIIa (Inhibitors)
7. Haemophilia Therapeutics Market - Major Clinical Milestones
  • Haemophilia Therapeutics Market - Major Ongoing/Recently Completed Clinical Trials
8. Haemophilia Therapeutics Market - Product Dashboard of Recently Approved and Late-stage Pipeline Drug Candidates
  • Eloctate - Biogen Idec/SOBI
  • NovoEight (Turoctocog alfa) - Novo Nordisk
  • BAX 111 - Baxter
  • BAX 855 - Baxter
  • BAY81-8973 - Bayer
  • Nuwiq/Human-cl rhFVIII (simotocog alfa) - Octapharma
  • BAY94-9027 - Bayer
  • N8-GP (turoctocog alfa pegol) - Novo Nordisk
  • rVIII - Single Chain - CSL Behring
  • Alprolix - Biogen Idec/SOBI
  • Rixubis - Baxter
  • rIX-FP - CSL Behring
  • IB1001 - Cangene (Emergent Biosolutions)
  • N9-GP (nonacog beta pegol) - Novo Nordisk
  • Obizur - Baxter
  • BAX 817 - Baxter
  • LR769 - rEVO Biologics/LFB
9. Haemophilia Therapeutics Market - Future Therapies and Novel Technologies to Extend Half-life
  • Novel Technologies that Extend Half-life of Factor Concentrates
  • Novel Pipeline Therapies - Gene Therapy
  • Novel Pipeline Therapies - RNA Interference
  • Novel Pipeline Therapies -Tissue Factor Pathway Inhibitor
10. Haemophilia Therapeutics Market - Timeline of Key Events
  • Haemophilia A Therapeutics (FVIII) Market - Timeline of Key Events
  • Haemophilia B Therapeutics (FIX) Market - Timeline of Key Events
  • Inhibitors (Bypassing Agents) (FVIIa) Market - Timeline of Key Events
11. Haemophilia Therapeutics Market - Key Companies to Watch
  • Leading Big Pharma Companies - SWOT Analysis Bayer
  • Leading Big Pharma Companies - SWOT Analysis Baxter
  • Leading Big Pharma Companies - SWOT Analysis Novo Nordisk
  • Leading Big Pharma Companies - SWOT Analysis Pfizer
  • Key Companies to Watch - SWOT Analysis Biogen Idec
  • Key Companies to Watch - SWOT Analysis CSL Behring
  • Comparative Product Analysis of Key Market Participants
12. Conclusions
  • Conclusions and Recommendations
  • Legal Disclaimer
13. Appendix
  • List of Abbreviations
Note: Product cover images may vary from those shown
3 of 3
- Alnylam Pharmaceuticals
- Amsterdam Molecular Therapeutics
- Baxter
- Bayer
- Biogen Idec
- Behring
- Cangene
- Chatham Technologies
- Novo Nordisk
- Octapharma
- Pfizer
- rEVO Biologics
Note: Product cover images may vary from those shown
Adroll
adroll